Acotiamide is a gastroprokinetic medication used mainly for the treatment of Functional Dyspepsia, a condition characterized by postprandial fullness, early satiety, and upper abdominal discomfort. It works by enhancing the release of acetylcholine in the gastrointestinal tract, thereby improving gastric motility and facilitating better digestion. Acotiamide was developed by Zeria Pharmaceutical Co., Ltd. and was first approved in Japan in 2013. It was introduced as a safer alternative to earlier prokinetic agents such as Cisapride, which were associated with serious cardiac side effects. Marketed under brand names like Acofide, Acotiamide has shown effectiveness in relieving symptoms like bloating and gastric discomfort in clinical studies. It primarily acts as an acetylcholinesterase inhibitor in the gut without significant central nervous system involvement, making it relatively well tolerated. Today, it is widely used, particularly in Asian countries, for managing functional gastrointestinal disorders.
